Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OOAPU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN117337196A Compound87
|
|||||
| Synonyms |
30kmPEG (SCAPDL1xSCACD47)-2 (Val-Cit-PAB-DEA-SN38)
Click to Show/Hide
|
|||||
| Organization |
Shenzhen Enduring Biotech Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1
|
|||||
| Structure |
|
|||||
| Antibody Name |
SCAPDL1xSCACD47
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
30kmPEG-Lys (PEG2 - Mal)-2 (Val-Cit-PAB-DEA-SN38)
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 10% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 15% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 20% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 30% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 40% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 42% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung squamous cell carcinoma | NCI-H520 cells | CVCL_1566 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition ratio | ≈ 50% | Positive CD47/PD-L1 expression (CD47/PD-L1+++/++) | ||
| Method Description |
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 87 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H661 cells | CVCL_1577 | ||